Abstract:Erythema dyschromicum perstans (EDP), described by Convit et al. in 1961, is a rare dermatosis. Its relationship with ashy dermatosis (AD), described by Ramirez in 1957, is still a matter of debate. We report a typical case of EDP. The patient, of North African origin, had a dyschromic (hypo- and hyperpigmented) eruption on the chest and limbs for 2 years. The lesions were occasionally surrounded by a papular border which spread slowly and centrifugally. Histological examination showed a lichenoid infiltrate. … Show more
“…The therapeutic options are many, but few have been effective,5,6,8,12–14,24,32,42–47 except possibly clofazimine 13,32 . Its beneficial effect may be mediated by anti‐inflammatory and immunomodulatory actions 32 .…”
“…The therapeutic options are many, but few have been effective,5,6,8,12–14,24,32,42–47 except possibly clofazimine 13,32 . Its beneficial effect may be mediated by anti‐inflammatory and immunomodulatory actions 32 .…”
“…The strictly defined segmental NF was termed NF5 in Riccardi's clinical classification of the neurofibromatoses into eight groups. 4 Broader definitions were given by Roth 5 and Combemale et al 6 Their classification schemes, however, which include heritable and non-heritable clinically distinguishable subtypes were not in agreement with genetic knowledge. A classification for neurofibromatoses into NF1, NF2, alternate and related forms of either NF1 or NF2 was proposed by Viskochil and Carey, 7 according to the present understanding of the molecular aspects of neurofibromatoses.…”
Segmental neurofibromatosis (NF) is generally thought to result from a postzygotic NF1 (neurofibromatosis type 1) gene mutation. However, this has not yet been demonstrated at the molecular level. Using fluorescence in situ hybridisation (FISH) we identified an NF1 microdeletion in a patient with segmental NF in whom café-au-lait spots and freckles are limited to a single body region. The mutant allele was present in a mosaic pattern in cultured fibroblasts from a café-au-lait spot lesion, but was absent in fibroblasts from normal skin as well as in peripheral blood leukocytes. These findings prove the hypothesis that the molecular basis of segmental cutaneous NF is a mutation in the NF1 gene and that the regional distribution of manifestations reflects different cell clones, commensurate with the concept of somatic mosaicism.
“…Ramirez in 1957 described a condition called “dermatosis cenicienta” (ashy dermatosis),[ 29 ] which presented with small greyish macules, and later in 1961, Convit et al . [ 30 ] described a dermatosis from Venezuela consisting of five cases characterized by large greyish macules with a papular, slowly extending erythematous border.…”
Acquired dermal macular hyperpigmentation (ADMH) is an umbrella term that includes disorders clinically characterized by small and large pigmented macules/patches and histopathologically showing an evidence of current or resolved interface dermatitis with pigment incontinence, without clinically significant prior inflammatory phase. The term intends to include diseases previously described in the literature as lichen planus pigmentosus, Riehl's melanosis/pigmented cosmetic dermatitis and ashy dermatosis/erythema dyschromicum perstans. The nomenclature and origin of these disorders have always been a matter of discussion. These disorders share many clinicopathological similarities, are difficult to treat and adversely affect the quality of life. Recent consensus points towards the need for a unifying term to facilitate research and therapeutic trials. This article aims to provide a comprehensive review of the recent advances in ADMH.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.